5A apoA-I mimetic peptide / Longevity Biotech, National Heart, Lung, and Blood Institute - LARVOL DELTA

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Cardiovascular

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Jun 2024 ➔ Jun 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Cardiovascular

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Jun 2023 ➔ Jun 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Cardiovascular

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - P1; N=64; Recruiting; Sponsor: National Heart, Lung, and Blood Institute (NHLBI); Trial completion date: Jun 2022 ➔ Jun 2023; Trial primary completion date: Jun 2022 ➔ Jun 2023

Clinical • Trial completion date • Trial primary completion date • Cardiovascular

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - P1; N=64; Recruiting; Sponsor: National Heart, Lung, and Blood Institute (NHLBI); Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Cardiovascular

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - P1; N=64; Not yet recruiting; Sponsor: National Heart, Lung, and Blood Institute (NHLBI); Trial completion date: Dec 2020 ➔ Jun 2022; Trial primary completion date: Dec 2020 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Cardiovascular

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers (clinicaltrials.gov) - P1; N=64; Not yet recruiting; Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Clinical • New P1 trial